BusinessAdmin•Yahoo Finance RSS•9 hours ago
Travere Therapeutics Director Reduces Stake After 168% Surge: Is FILSPARI's Revenue Growth Just Beginning?
A Travere Therapeutics director has trimmed their stake after a significant stock surge, prompting speculation about the future revenue potential of FILSPARI.
- • A director at Travere Therapeutics has sold a portion of their shares following a remarkable 168% increase in stock value.
- • This sale raises questions about the future revenue potential of FILSPARI, Travere's key product.
- • Despite the director's stake reduction, analysts believe that FILSPARI's revenue growth may be in its early stages, suggesting a positive outlook for the company's financial performance.
Source: Yahoo Finance RSS
Read original →
